Of the new generation platinum compounds that have been evaluated, those with the 1, 2-
diaminocyclohexane carrier ligand–including oxaliplatin–have been focused upon in recent …

Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing
intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity …

Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-
fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5 …

Oxaliplatin is a cytotoxic agent which, like other platinum compounds, acts primarily by
causing inter-and intra-strand cross-links in DNA, thereby inhibiting DNA synthesis …

For the past 40 years, the mainstay of chemotherapy against colorectal cancer has been 5-
fluorouracil (5-FU), often administered in recent years with folinic acid modulation …

Oxaliplatin (Eloxatin; Sanofi, Gentilly, France), a third-generation platinum compound with a
1, 2-diaminocyclohexane (DACH) carrier ligand, is a recently developed agent with activity …

Oxaliplatin, the first available diaminocyclohexane platinum, has clinical activity in colorectal
and ovarian cancers. Its mechanism of action is thought to be similar to that of cisplatin, its …

Colorectal cancer is one of the leading causes of death from malignant diseases in the
Western world. Worldwide,∼ 50% of patients who present with colorectal cancer will …

Oxaliplatin (Eloxatin™), a recently developed third-generation cisplatin analogue with a 1, 2-
diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in …

Introduction: Oxaliplatin, a second-generation platinum analog, has evolved as one of the
most important therapeutic agents in colorectal cancer (CRC) treatment. It has had a major …